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 INTRODUCTION 
 
 Living organisms require a relatively steady energy supply to sustain biological functions. 
Moreover, energy reserves must not only be sufficient to serve all physiological needs, but 
must also be wisely allocated to a wide variety of often competing physiological functions (1). 
Energy intake and energy expenditure undergo substantial daily and seasonal fluctuations, 
however.  
Immunity requires adequate and balanced energy supply for optimal function (2). Although 
the risk of infection and death is highest when energy reserves are not sufficient (3), obesity, a 
state of energy excess, has also been associated with increased susceptibility to infection, 
bacteremia, and poor wound healing (4).  
The discovery of the adipocyte-derived hormone leptin, the levels of which reflect the amount 
of energy stored in the adipose tissue and are altered by conditions such as fasting and 
overfeeding, has proved to be fundamental to our understanding of the concept of energy 
availability influencing several physiological systems. More specifically, the past few years of 
research on leptin — the product of the obese (ob) gene — have provided important insights 
into the intricate network that links nutrition, metabolism and immune homeostasis (5). Leptin 
is mainly produced by the adipose tissue in proportion to the body fat mass and, at lower 
levels, by tissues such as the stomach, skeletal muscle and placenta (5). Although an 
important role of leptin is to regulate body weight through the inhibition of food intake and 
stimulation of energy expenditure by increased thermogenesis, recent evidence has indicated 
that leptin is much more than a 'fat-o-stat' sensor (6). Indeed, leptin-deficient (ob/ob) mice and 
leptin-receptor-deficient (db/db) mice are not only severely obese, but also have a series of 
marked abnormalities that are secondary to the effects of leptin on reproduction (7), 
haematopoiesis (8), angiogenesis (9,10), insulin secretion (5), metabolism of bone (11), lipids 
and glucose (1) and, last but not least, innate and adaptive immunity. 
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Leptin as a neuroendocrine and immune mediator 
 
Leptin is a 16-kDa nonglycosylated protein encoded by the obese (ob) gene, which is located 
on human chromosome 7 and on mouse chromosome 6 (5). In both humans and mice, 
mutations of the ob gene are associated with hyperphagia and obesity, reduced energy 
expenditure, and other reproductive, neuroendocrine, and metabolic dysfunction. Serum leptin 
is usually higher in obese individuals and has a strong sexual dimorphism, being higher in 
females than males matched by age and body weight (5). 
Leptin is classically considered a hormone because it regulates the balance between food 
intake and energy expenditure, signalling to the brain the changes in stored energy. 
Synthesized primarily by the white adipose tissue, leptin is secreted at lower levels by the 
gastric mucosa, placenta, mammary epithelium, and skeletal muscle (5). Leptin gene 
expression is regulated by several factors, including other hormones. Insulin stimulates leptin 
secretion during feeding, while a decrease in insulin levels anticipates a fall in leptin during 
starvation (5). Moreover, leptin expression is inhibited by testosterone, increased by ovarian 
sex steroids, and directly influences the hypothalamic-pituitary-adrenal axis, the reproductive 
system, hematopoiesis, and angiogenesis (5).  
Many studies have linked the immune and neuroendocrine systems (12, 13). Physiological 
responses to stress usually involve finely integrated interactions between the autonomic 
nervous system and the Hypthalamo-Pituitary-Adrenal (HPA) Axis, and the immune system 
and metabolism (12, 13). For example, peripheral inflammation stimulates the central release 
of corticotrophin-releasing hormone (CRH), which in turn regulates the stress response 
through the production of adrenocorticotrophic hormone (ACTH) — a hormone that promotes 
the synthesis and release of Glucocorticoids from the adrenal glands. The glucocorticoids — 
hormones that get their name from their ability to raise levels of blood glucose — have potent 
anti-inflammatory effects and dampen humoral and cell-mediated immune responses. 
Interestingly, mediators that are common to the neuroendocrine and immune systems, such as 
the cytokines interleukin-1 (IL-1), IL-6 and tumour-necrosis factor (TNF), can all modulate 
inflammation through the HPA axis (12, 13). Indeed, these peripherally derived cytokines can 
cross the blood–brain barrier and act on the hypothalamus and pituitary gland to regulate the 
secretion of ACTH in response to inflammation. These cytokines also mediate a negative 
feedback on their own peripheral pro-inflammatory activity and are counter-regulated by 
endogenous glucocorticoids produced by the HPA axis. 
 5 
 
Leptin is one of the mediators that are common to the neuroendocrine and immune systems 
(14). In the immune system, leptin, together with C- Reactive Protein (CRP), IL-1 and IL-6, 
can act as an early acute-phase reactant, produced at high levels during inflammation, sepsis 
and fever, and it can be induced by other inflammatory mediators such as TNF and IL-1 (15-
21). However, although these findings have been demonstrated in several systems, other 
studies have not found increased leptin in inflammatory conditions in humans, including acute 
experimental endotoxaemia, newborn sepsis, HIV infection and during anti-inflammatory 
therapy (22-24). So, although leptin has well documented pro-inflammatory properties, it 
seems that it might act as an acute-phase reactant in some conditions and not in others. 
The neuroendocrine role of leptin is most evident in conditions such as fasting — during 
which the production of leptin by adipose tissue is markedly reduced — or in relation to the 
effects of sex hormones on its production (testosterone reduces the secretion of leptin, 
whereas oestrogens increase its production). The link between leptin and sex hormones is also 
indicated by the marked gender dimorphism, manifested by a higher serum concentration in 
females than in males with similar body fat mass. 
The fact that leptin has effects on both the neuroendocrine and immune systems should not 
come as a surprise, given the functional connection and anatomical contiguity between 
adipocytes and lymphoid cells (6). Morphologically, aggregations of lymphoid tissue, 
including the lymph nodes, omentum, thymus and bone marrow, are associated with adipose 
tissue (6). Fat deposits do not simply have a structural, metabolic and heat-insulating function, 
but provide a microenvironment that helps the immune system to sustain immune responses 
(6). In particular, lymphoid and adipose tissue interact locally through common mediators 
known as adipokines — adipocyte-derived molecules that bridge metabolism and immune 
homeostasis (these molecules include leptin, adiponectin, chemokines and other pro-
inflammatory cytokines). For example, TNF and chemokines promote the differentiation of 
adipose tissue and leptin secretion, which in turn sustains the differentiation of T helper 1 
(TH1) cells (see later) (25, 26). 
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Leptin signaling in immune cells   
 
 Leptin, as previously mentioned, is mainly secreted by the adipose tissue, which is also 
present within both primary and secondary lymphoid organs and has a significant metabolic 
and immunomodulatory role (27, 28). Leptin’s three-dimensional structure is similar to that of 
a cytokine consisting of a four -helix bundle motif (which is common to the IL-6, IL-12, IL-
15 family of cytokines) (29). Leptin receptor (ObR), is also a member of the class I cytokine 
receptor superfamily and has at least six isoforms as a result of alternative splicing with 
cytoplasmatic domains of different length, known as OBRa, OBRb, OBRc, OBRd, OBRe and 
OBRf (30, 31). These receptors are membrane-spanning glycoproteins with fibronectin type 
III domains in the extracellular region and with a shared 200-amino-acid module containing 
four conserved cysteine residues and two membrane proximal cytokine-like binding motifs, 
Trp-Ser-Xaa-Trp-Ser (30, 31). The short forms of the leptin receptor are expressed by several 
non-immune tissues and seem to mediate the transport and degradation of leptin. The long 
form of OBR, known as OBRb, is the only form able to transduce the signal and is expressed 
by the hypothalamus in areas that are responsible for the secretion of neuropeptides and 
neurotransmitters that regulate appetite, body weight (30, 31) and bone mass (11). 
Interestingly, OBRb is also expressed by endothelial cells, pancreatic β-cells, the ovary, 
CD34+ haematopoietic bone-marrow precursors, monocytes/macrophages, and T and B cells 
(5, 9, 10, 30, 31). The expression of OBRb by T and B cells is of interest as it indicates a 
possible role for leptin in immune-cell activation and signal transduction, and might unveil 
new effects of leptin on as-yet-unexplored immune-cell functions (32, 33, 34). After binding 
leptin, OBRb-associated Janus-family tyrosine kinase 2 (JAK2) becomes activated by auto- or 
cross-phosphorylation and tyrosine phosphorylates the cytoplasmic domain of the receptor. 
Four of the phosphorylated tyrosine residues function as docking sites for cytoplasmic 
adaptors such as signal transducer and activator of transcription (STAT) factors, particularly 
STAT3 (in some cases, also STAT1 and STAT5) (30, 34) (Figure 1).  
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Fig.1 Schematic representation of leptin signaling 
 
 
The membrane distal tyrosine (position 1138) functions as a docking site for STAT3, 
which is a substrate of JAK2. After subsequent dimerization, STAT3 translocates to the 
nucleus and induces the expression of suppressor of cytokine signalling 3 (SOCS3) and other 
genes. SOCS3 takes part in a feedback loop that inhibits leptin signalling by binding to 
phosphorylated tyrosines. SRC homology 2 (SH2) domain-containing phosphatase 2 (SHP2) 
is recruited to Tyr985 and Tyr974, and activates extracellular signal-regulated kinase 1/2 
(ERK1/2) and p38 mitogen-activated protein kinase (MAPK) pathways through the adaptor 
protein growth factor receptor-bound protein 2 (GRB2), ultimately inducing the expression of 
FOS and JUN (30-37). After leptin binding, JAK2 can induce phosphorylation of the insulin 
receptor substrate 1/2 (IRS1/2) proteins that are responsible for the activation of 
phosphatidylinositol 3-kinase (PI3K) (30, 37) (Figure 1). Moreover, Src associated in mitosis 
protein (Sam68), an RNA-binding protein, regulator of RNA metabolism and effector of the 
PI3'K is currently thought to function as an adaptor protein by binding to activated STAT-3 
and to the p85 subunit of PI3'K (35) Phosphotyrosine phosphatase 1B (PTP1B), which is 
localized on the surface of the endoplasmic reticulum, is involved in negative regulation of 
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OBRb signalling through the dephosphorylation of JAK2 after internalization of the OBRb 
complex. 
 
Leptin in innate and adaptive immunity 
 
 Mice lacking leptin or its functional receptor have a number of defects in both cell-
mediated and humoral immunity (38, 39). Similarly, humans with congenital leptin deficiency 
have a much higher incidence of infection-related death during childhood (40), whereas 
recombinant human leptin (rmetHuLeptin) administration in two children with congenital 
leptin deficiency normalized absolute numbers of naive CD4+CD45+RA T cells and nearly 
restored the proliferation response and the cytokine release profile from their lymphocytes 
(41). A number of studies in mice have shown that the effect of leptin on the immune system 
is both direct and indirect, i.e., via modulation of central or peripheral pathways (42, 43) 
(Figure 2). Leptin seems to promote activation of and phagocytosis by 
monocytes/macrophages and their secretion of leukotriene B4 (LTB4), cyclooxygenas 2 
(COX2), nitric oxide and pro-inflammatory cytokines (44, 46). The products of the inducible 
form of COX2 — prostaglandins and leukotrienes (also known as eicosanoids) — as well as 
nitric oxide, are all involved in the regulation of inflammation, chemotaxis and cytokine 
production, and therefore markedly impact the immune response (44, 46). Moreover, leptin 
can induce chemotaxis of neutrophils and the release of oxygen radicals (such as superoxide 
anion and hydrogen peroxide) (47, 48).These mediators can be particularly harmful to cells, 
as they can denature proteins and damage membrane lipids (by peroxidation of unsaturated 
fatty acids), carbohydrates and nucleic acids. At least in human neutrophils, leptin seems to 
mediate its effects through an indirect mechanism, probably involving the release of TNF 
from monocytes (49). Leptin also affects natural killer (NK)-cell development and activation 
both in vitro and in vivo (50, 52). As NK cells express OBRb and db/db mice have a deficit of 
NK cells resulting from abnormal NK-cell development, it is possible that leptin might 
influence the development/maintenance of a normal peripheral NK-cell pool. Indeed, an 
important role of OBRb in NK-cell physiology is indicated by the ability of OBRb to 
influence NK-cell cytotoxicity through direct activation of signal transducer and activator of 
transcription 3 (STAT3) and the transcription of genes encoding IL-2 and perforin (50-52). 
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Figure 2.  Schematic representation of the effects of leptin on both innate and adaptive immunity. 
 
 
 
Last but not least, it has recently been shown that leptin can stimulate the production of 
growth hormone by peripheral-blood mononuclear cells (PBMCs) through protein kinase C 
(PKC) and nitric oxide-dependent pathways (46). This effect of leptin on the production of 
growth hormone might be important in immune homeostasis, given the fact that this cytokine-
like hormone has marked influences on immune responses by controlling the survival and 
proliferation of immue cells (46).  
The effects of leptin on adaptive immune responses have been extensively investigated on 
human CD4+ T cells (Figure 2). Addition of physiological concentrations of leptin to a Mixed 
Lymphocytes Reaction (MLR) induces a dose-dependent increase in CD4+ T-cell 
proliferation. However, leptin has different effects on proliferation and cytokine production 
by human naive (CD45RA+) and memory (CD45RO+) CD4+ T cells (both of which express 
OBRb). Leptin promotes proliferation and IL-2 secretion by naive T cells, whereas it 
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minimally affects the proliferation of memory cells (on which it promotes a bias towards 
TH1-cell responses) (53). Furthermore, leptin increases the expression of adhesion molecules, 
such as intercellular adhesion molecule 1 (ICAM1, CD54) and very late antigen 2 (VLA2, 
CD49B), by CD4+ T cells, possibly through the induction of pro-inflammatory cytokines such 
as interferon-γ (IFN-γ). Increased expression of adhesion molecules could then be responsible 
for the induction of clustering, activation and migration of immune cells to sites of 
inflammation (53). Another important role of leptin in adaptive immunity is highlighted by 
the observation that leptin deficiency in ob/ob mice is associated with immunosuppression 
and thymic atrophy — a finding similar to that observed in acute starvation. Acute caloric 
deprivation causes a rapid decrease of serum leptin concentration accompanied by reduced 
Delayed-Type-Hypersensitivity (DTH) responses and thymic atrophy, which are reversible 
with administration of leptin (54, 55). The thymic atrophy in ob/ob mice (or wild-type starved 
animals) affects the cortex of the thymus, in which most CD4+CD8+ T cells are found, and 
leptin replacement reduces the rate of apoptosis of such cells (54). Despite the evidence of 
direct effects of leptin on immune responses in vitro, a major problem remains in ascertaining 
whether leptin can influence immune responses in vivo. This task is particularly difficult 
because of the complexity of the network of interactions that link leptin to several endocrine 
pathways. For example, the immune abnormalities associated with high cortisol levels and 
hyperglycaemia in obese ob/ob or db/db mice could simply be a consequence of obesity rather 
than direct effects of leptin (55). To help clarify this issue, studies of food restriction, which 
can reduce cortisol and glucose levels in ob/ob mice, have shown that only leptin replacement 
can fully restore normal immune responses in ob/ob mice, whereas experimentally induced 
reduction of serum levels of cortisol and glucose cannot reverse immune abnormalities (55). 
Although still controversial, these observations seem to indicate that the immune 
abnormalities in ob/ob mice cannot be simply ascribed to high circulating levels of cortisol 
and glucose, and that leptin might instead have direct effects on the immune system that are 
independent of the metabolic abnormalities associated with leptin deficiency (55). 
 
 
 
 
 
 
 
 11 
CD4+ T cells in immunity 
 
 The CD4 cell surface marker has come to be associated with a varied group of 
lymphocytes that orchestrate both innate and adaptive immune responses to pathogens and 
tumors through a variety of mechanisms. The prototypic member of this group is the CD4+ T-
helper (Th) lymphocyte subset, which augments both humoral and cellular immune responses 
(56, 57). Th cells recognize antigen as peptide epitopes of approximately 12–20 residues long, 
presented by major histocompatibility complex class II (MHC-II) molecules typically found 
on specialized antigen-presenting cells (APCs) such as dendritic cells (DCs), macrophages, 
and B cells (58). In some instances, Th cells can directly recognize antigen on MHC-II-
expressing tumor cells, resulting in the production of lymphokines that hinder tumor growth 
or inducing tumor cell death (59, 61). 
Naive CD4+ Th lymphocytes develop in the thymus following a controlled developmental 
path involving both positive and negative selection to cull potentially autoreactive cells from 
the repertoire while maintaining the ability to recognize a broad range of pathogen-associated 
peptides presented by self MHC-II molecules. During an immune response, recognition of the 
cognate antigen presented on the surface of an APC by the T-cell receptor for antigen (TCR) 
(Signal 1) along with interaction between appropriate costimulatory molecules such as the 
CD28 co-receptor with CD80/CD86 (Signal 2) initiates activation of the naive CD4+ T cell. 
These activated T cells undergo a phase of robust clonal expansion and differentiation into 
either effector or memory cells. CD4+ memory Th cells can be classified into two main 
groups based on cell surface markers and functional capacities. Central memory Th cells 
(ThCM) express high levels of CCR7 and CD62L, lack CD45RA, and traffic through the 
lymphoid organs (62, 64). Effector memory T cells (ThEM) are CCR7 negative and reside 
mostly in the blood, spleen, and in non-lymphoid tissues (65). Long-term survival of memory 
Th cells relies on the participation of costimulatory molecules (OX40/OX40L) and the 
availability cytokines such as interleukin-7 (IL-7) (66, 68). 
 The fate and function of the activated Th cells depends in large part upon the 
microenvironment present at the time of the initial antigen encounter. The composition of the 
local cytokine milieu will bias development toward one of several alternative differentiation 
pathways. Likewise, the nature of the antigen acquired by DCs will affect the expression of 
different sets of costimulatory molecules, which will also dictate the developmental path of 
the antigen-stimulated Th cells (69). This additional polarizing costimulation has been termed 
'Signal 3' and is initiated by various innate pathogen-associated molecular pattern receptors 
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triggered by the various antigens (70,72). For example, DC exposure to intracellular 
pathogens programs these APCs to promote Th1-type responses, whereas exposure to 
helminthes drives DCs to promote Th2 development. A similar situation may exist for the 
other various regulatory subsets of Th cells (73). 
 CD4+ T lymphocytes can be grouped into different functional subsets based on function 
and cytokine secretion patterns (Figure 3). Originally, CD4+ T cells were simply classified as 
Type 1 effector Th cells (Th1) that produce high levels of interferon-γ (IFN-γ) and tumor 
necrosis factor-α (TNF-α) upon antigen stimulation and being responsible for regulating 
delayed type hypersensitivity (DTH) reactions and cell-mediated immunity to intracellular 
pathogens and tumor cells. The Th1 developmental pathway is driven by IL-12 activation of 
signal transducer and activator of transcription 4 (Stat4) and T-bet during immune activation 
of naive T cells (74). Alternatively, Th2 are characterized by the production IL-4, IL-5, and 
IL-13 and are responsible for coordinating humoral immunity, eosinophilic inflammation, and 
controlling helminthic infections. IL-4 is primarily accountable for the differentiation of Th2 
cells through Stat6 and GATA (75). The Th1 and Th2 developmental pathways are controlled 
by a delicate balance of positive feedback loops, as IFN-γ enhances further Th1 development 
and IL-4 supports continued Th2 differentiation. At the same time, cross-regulation by IFN-γ 
and IL-4 suppresses Th2 and Th1 differentiation, respectively. In addition to Th1 and Th2 
cells, several other subsets of CD4+ T cells participate in the development of immune 
responses. In many instances, these cells act to control/suppress immune responses and play 
an important role in the prevention of autoimmune diseases. The best-studied group is the 
naturally occurring CD4+CD25+ T-regulatory cells (Tregs) (76, 78). Approximately 5–6% of 
the CD4+ T cells exiting from the thymus express high levels of CD25, glucocorticoid-
induced TNF receptor (GITR), and the transcription factor forkhead box protein 3 (Foxp3) 
(79, 81). These Tregs mediate immune suppression through a cell-to-cell contact-dependent 
mechanism that does not require antigenic stimulation (82). While important for the 
prevention of autoimmunity, in some circumstances Tregs hinder desirable immune 
responses, for example against tumor-associated antigens. Depletion of this subset in vivo, for 
example with anti-CD25 monoclonal antibodies, enhances anti-tumor immunity in mice (83, 
87), specially when the targeted tumor antigens are expressed to some extent by normal cells 
(e.g. tissue differentiation antigens or products of overexpressed genes). Antigen-experienced 
CD4+ T cells can also develop into Tregs that express CD25, Foxp3, and GITR. Although the 
origins of these adaptively induced Tregs is unclear, they have similar immune suppressive 
effects as their naturally occurring counterparts. Another subset of regulatory CD4+ T cells 
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called Th17 has been described recently (88). The evidence suggests that Th17 cells develop 
independently from either Th1 or Th2 cells and represent a distinct lineage (89).  
 
 
Figure. 3.   Diversity of CD4-expressing cell subsets. The main CD4+ T-cell subsets develop from naive CD4+ 
T cells after antigen-dependent T-cell activation. The microenvironment present during priming, including 
antigen dose, APC type, cytokines, and costimulatory signals, all influence the developmental pathway taken by 
the responding T cell. The major cytokines and secreted factors contributing to the respective functions of the Th 
subsets are listed to the right of each cell type. (Kennedy, R and Celis, E 2008 Immunol Reviews) 
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Leptin in Autoimmunity  
 
 As mentioned earlier, ob/ob mice have several abnormalities that are common to starved 
animals (5). However, ob/ob (and db/db) mice also have additional endocrine and metabolic 
disturbances that could affect the immune system indirectly, such as hypercorticosteronaemia 
and diabetes (5). Similarly, starvation not only associates with hypoleptinaemia, but also with 
an increased concentration of glucocorticoids and decreased levels of thyroid and growth 
hormones (which can result in immune suppression) (5). So, the effects of leptin on the 
immune system should take into account both the direct and indirect effects of this molecule 
on other hormones. Although the influence of thyroid and growth hormones on the effects of 
leptin remains elusive, it seems that leptin can affect thymic output and T-cell function 
independently of glucocorticoids, as congenitally leptin-deficient individuals have 
glucocorticoid levels within a normal range, but markedly reduced numbers of naive T cells 
(5).  
More importantly, ob/ob mice have reduced secretion of IL-2, IFN-γ, TNF and IL-18, and 
increased production of TH2-type cytokines, such as IL-4 and IL-10, after mitogenic 
stimulation. As a result, ob/ob mice are resistant to the induction of several experimentally 
induced autoimmune diseases, for example, AIA (Antigen-Induced Arthritis), which is a 
model of immune-mediated joint inflammation induced by administration of methylated 
bovine serum albumin (mBSA) into the knees of immunized mice (90). The severity of 
arthritis in leptin and leptin-receptor-deficient mice was reduced. The milder form of AIA 
seen in ob/ob and db/db mice, as compared with controls, was accompanied by decreased 
synovial concentrations of IL-1β and TNF-α (Th1-type cytokines), decreased in vitro 
proliferative response to antigen in lymph node cells, and a switch toward the production of 
Th2 cytokines (90). Serum levels of anti-mBSA antibodies were also significantly decreased 
in the arthritic  ob/ob mice, as compared with controls. 
Thus, in AIA, leptin may probably contribute to joint inflammation by regulating both 
humoral and cell-mediated immune responses. However, joint inflammation in AIA depends 
on adaptive immune responses, which are impaired in ob/ob and db/db and mice. More recent 
studies have investigated the effect of leptin and leptin receptor deficiency on the 
inflammatory events of zymosan-induced arthritis (ZIA), a model of proliferative arthritis 
restricted to the joint injected with zymosan A and not dependent on adaptive immune 
responses (91). ZIA, in contrast to AIA, was not impaired in ob/ob and db/db mice. However, 
the resolution of acute inflammation was delayed in the absence of leptin or leptin signaling, 
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suggesting that leptin could exert beneficial influences on the evolution of this model of 
arthritis (92). 
In humans, patients with rheumatoid arthritis (RA) with reduced serum leptin levels induced 
by fasting reportedly had improved clinical and biological measures of disease activity 
associated with a decrease of CD4+ lymphocyte activation and a shift toward Th2 cytokine 
production (93). These aspects, resembling somehow those seen in AIA in ob/ob mice, 
suggested that leptin could also influence inflammatory arthritis in humans through an 
influence on Th1 responses.  
Ob/ob mice are also protected from Expeimental Autoimmune Encefalomylaitis (EAE), 
whereas administration of leptin to susceptible wild-type mice worsens EAE by increasing the 
secretion of pro-inflammatory cytokines and directly correlates with pathogenic T-cell 
autoreactivity (see later for further details). Protection of ob/ob mice from autoimmunity is 
also observed in Experimentally Induced Hepatites (EIH) (93, 94). Activation of T cells and 
macrophages is one of the initial events during viral or autoimmune hepatitis. Activated T 
cells are directly cytotoxic for hepatocytes and release proinflammatory cytokines, which 
mediate hepatocyte damage. A well-described mouse model of T-cell-dependent liver injury 
is the one induced by i.v. injection of the T cell mitogen concanavalin A (Con A), which 
results in fulminant hepatitis. During Con-A-induced hepatitis, TNF-α is a crucial cytokine in 
the acute disease process because neutralization of this cytokine reduces liver damage. On the 
other hand, the injection of TNF-α causes acute inflammatory hepatocellular apoptosis 
followed by organ failure, and TNF-α thus appears to cause hepatoxicity. Siegmund et al. (94) 
showed that leptin-deficient ob/ob mice were protected from Con-A-induced hepatitis. TNF-α 
and IFN-γ levels, as well as expression of the activation marker CD69, were not elevated in 
ob/ob mice following administration of Con A, suggesting that their resistance was associated 
with reduced levels of those proinflammatory cytokines, together with low percentages of 
intrahepatic NKT cells (which are cells that contribute to progression of this disease) (94). 
Similar results were obtained in EIH induced by Pseudomonas aeruginosa exotoxin A 
administration (93). Also in this case, leptin administration restored responsiveness of ob/ob 
mice to EIH, and T lymphocytes and TNF-α were required for the induction of liver injury. 
The authors also showed that leptin played an important role in the production of two 
proinflammatory cytokines in the liver, namely TNF-α and IL-18 (91). Finally, ob/ob mice are 
resistant to acute and chronic intestinal inflammation induced by dextran sodium sulphate and 
to colitis induced by trinitrobenzene sulphonic acid (Experimentally Induced Colites, EIC) 
(95). In acute EIC, ob/ob mice do not develop intestinal inflammation and show decreased 
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secretion of pro-inflammatory cytokines and chemokines. As expected, leptin replacement 
increases cytokine production to the levels observed in control mice (95). Of interest, recent 
reports have shown that leptin secreted by the gastric mucosa is not completely degraded by 
proteolysis and can therefore reach the intestine in an active form, where it can control the 
expression of sodium/glucose and peptide transporters on intestinal epithelial cells (96, 97). 
As a result, leptin might have a dual nature: on one hand, leptin could function as a growth 
factor for the intestine, because of its involvement in the absorption of carbohydrates and 
proteins; on the other hand, leptin could function as a mediator of intestinal inflammation (95, 
97). 
More recently, protection from autoimmunity in ob/ob mice has been observed in 
Experimentally Induced Glomeruloneprhites (98). In this immune-complex-mediated 
inflammatory disease induced by injection of sheep antibodies specific for mouse glomerular 
basement membrane into mice preimmunized against sheep IgG, the authors observed renal 
protection of ob/ob mice associated with reduced glomerular crescent formation, reduced 
macrophage infiltration, and glomerular thrombosis. These protective effects were associated 
with concomitant defects of both adaptive and innate immune response (testified by reduced 
in vitro proliferation of splenic T cells and reduced humoral responses to sheep IgG, 
respectively). Finally, evidence that leptin may exert pathogenic effects in immune-mediated 
disorders of the kidney come from the finding that leptin is a renal growth and profibrogenic 
factor that contributes to endocapillary proliferation and subsequent development of 
glomerulosclerosis during renal damage in conditions possibly including diabetes and obesity, 
both characterized by high circulating leptin levels (99). 
All these studies concern a role for leptin in experimentally “induced” autoimmunity. 
However, leptin is also important in “spontaneous” autoimmune Diabetes in non-obese 
diabetic (NOD) mice (100). Leptin accelerates autoimmune diabetes in females NOD/LtJ 
mice (101, 102). Fluctuations in serum leptin levels have been also observed in a study 
performed by our group in an animal model of CD4+ T cell-mediated autoimmune disease, 
such as type 1 diabetes (T1D). Non-obese diabetic (NOD/LtJ) female mice, spontaneously 
prone to the development of beta-cell autoimmunity, have higher serum leptin levels, as 
compared to NOD/LtJ males and non-susceptible strains of mice, and show a serum leptin 
surge preceding the appearance of hyperglycaemia (101). Furthermore, early in life leptin 
administration significantly anticipated the onset of diabetes and increased mortality and 
inflammatory infiltrates in beta-islets; this phenomenon correlated with increased secretion of 
IFN-γ in leptin-treated NOD mice (101). More recently, it has been found that a natural leptin 
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receptor mutants of the NOD/LtJ strain of mice (named NOD/LtJ-db5J) display reduced 
susceptibility to T1D (103, 104). These data further support the role of leptin in the 
pathogenesis of T1D. These NOD-db5J mice are obese, hyperphagic and show 
hyperglycaemia associated with hyperinsulinaemia. The leptin receptor mutation affects the 
extracellular domain  of the leptin receptor probably impairing the leptin-binding and/or 
receptor dimerization. This effect is likely able to alter the intracellular signalling machinery, 
thus impairing the pathogenicity of anti-islets autoreactive T cells. Indeed, these mice show 
mild-low grade infiltration of the islets. This model nicely complements the previously 
published data from our group, hypothesizing a key role for leptin in the development of T1D. 
Further studies are needed to address the molecular machinery determining the phenotype of 
resistance observed in these mice as well as the possibility to interfere with T1D pathogenesis 
by blocking the leptin axis. 
Another indication that leptin could be involved in autoimmunity is the sexual dimorphism of 
serum leptin concentration (higher in females than in males matched for age and body mass 
index). In this sense, leptin could be added to the list of hormones, such as oestradiol and 
prolactin, that have long been known to have a role in favouring the predisposition of females 
to the development of autoimmunity (105). In particular, only hyperleptinaemic female mice 
develop autoimmunity, whereas hypoleptinaemic mice are protected, and treatment of EAE-
resistant SJL/J males with recombinant leptin renders them susceptible to EAE (105). 
 
Leptin in organ-specific autoimmunity of the central nervous system: the case of 
Multiple Sclerosis and EAE. 
 Immunologists look at multiple sclerosis as an autoimmune disease, in which T-
lymphocytes specific for myelin antigens start an inflammatory reaction in the central nervous 
system, which ultimately leads to demyelination and subsequent axonal injury. This view of 
multiple sclerosis as a T-cell-mediated autoimmune disease is derived primarily from studies 
on a single animal model, experimental autoimmune encephalomyelitis (EAE). The origins of 
EAE date back to the 1920s, when Koritschoner and Schweinburg induced spinal cord 
inflammation in rabbits by inoculation with human spinal cord. Since then EAE was elicited 
in many different species, including rodents and primates, and from these studies it became 
clear that EAE can reproduce many of the clinical, neuropathological and immunological 
aspects of multiple sclerosis (106).  
Multiple Sclerosis (MS) is a chronic, immune-mediated, inflammatory disorder of the central 
nervous system (CNS)  (107). Clinically the illness may present as a relapsing–remitting 
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disease, or with steady progression of neurological disability. The subsequent course of 
disease is unpredictable, although most patients with a relapsing–remitting disease will 
eventually develop secondary progressive disease.  Its pathology is, in part, reflected by the 
formation of focal inflammatory demyelinating lesions in the white matter, which are the 
characteristic hallmarks in patients with acute and relapsing disease (108, 109). In patients 
with progressive disease, the brain is affected in a more global sense, with diffuse but 
widespread (mainly axonal) damage in the normal appearing white matter and massive 
demyelination also in the grey matter, in particular in the cortex (110, 111). The mechanisms 
of tissue injury in focal white matter lesions are heterogeneous, resulting in patterns of 
demyelination that vary between patients or patient subgroups (108). The destruction patterns 
in the multiple sclerosis plaque can include a cytotoxic attack via T-cell and macrophages 
inflammation (with the secretion of perforin and granzyme as effector molecules directed 
towards the target), as well as a humoral-mediated destruction of the myelin sheat via local 
deposition of antibodies, which then can activate complement (Figure 4). Furthermore, there 
is a high inter-individual variability in the extent of axonal damage as well as remyelination 
and repair. The reason for this complex situation is largely unknown, although it is likely that 
genetic factors influencing immune-mediated inflammation as well as neuronal and glial 
survival may play a major role in modulating the phenotype of the disease (108). 
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Figure 4. Destruction patterns in the multiple sclerosis plaque. A) In the healthy CNS oligodendrocytes 
enheathe the axon and form myelin internodes of regular size. B) Cytotoxic attack can destry the myelin sheat 
via T-cell and macrophage inflammation. Cytotoxic T cells secrete perforin and granzyme as effector molecules 
directed towards the target (left). Humoral factors destry the myelin sheat via local deposition of antibodies, 
which then activate complement (right) or phagocytic effector cells via ADCC (not shown). C) Damage towards 
the oligodendrocyte and the axon is mediated via cytotoxic products of macrophages/microglia (left), with nitric 
oxide (NO) as one of the major constituents. Note that the oligodendrocyte shows typical morphology of 
apoptosis. On the right side, the diffuse pattern of axonal and myelin destruction is illustrated, where as yet no 
unequivocal pathogenetic mechanism has been identified. 
 
 
 As previously said, the most studied model of MS in animals is EAE, in which 
autoimmunity to CNS components is induced in susceptible strains of mice through 
immunization with self-antigens derived from basic myelin protein. The disease is 
characterized by autoreactive T cells that traffic to the brain and to the spinal cord and injure 
the myelin sheaths of CNS, with the result of chronic or relapsing-remitting paralysis 
(depending on the antigen and the strain of mice used). It has long been known that myelin-
reactive Th1 CD4+ cells can induce and/or transfer disease, and Th1 cytokines are elevated in 
the CNS inflammatory lesions of EAE. In contrast, Th2 cytokines typically associate with 
recovery from EAE and/or protection from the disease (112). It has been shown that leptin is 
involved in both the induction and in the progression of EAE (112). Genetically, leptin-
deficient ob/ob mice are resistant to induction of both active and adoptively transferred EAE. 
This protection is reversed by leptin administration and associates with a switch from Th2- to 
Th1-type responses and IgG1 to IgG2a isotype switch. Similarly, in susceptible wild-type 
C57BL/6J mice, leptin worsens disease by increasing IFN-γ release and IgG2a production 
(112). Importantly, a surge of serum leptin anticipates the onset of clinical manifestations of 
EAE (113). The peak of serum leptin correlates with inflammatory anorexia, weight loss, and 
the development of pathogenic T cell responses against myelin (113). Lymphomononuclear 
infiltrates in the CNS of EAE mice indicate in situ production of leptin in active inflammatory 
lesions, thus representing a significant local source of leptin (113) (Figure 5). Systemic 
and/or in situ leptin secretion was instead lacking in EAE-resistant mice. Taken together, 
these data suggest an involvement of leptin in CNS inflammation in the EAE model of MS. In 
the human disease, it has been reported that the secretion of leptin is increased in both serum 
and cerebrospinal fluid (CSF) of naive-to-treatment patients with MS, an aspect that 
positively correlates with the secretion of IFN-γ in the CSF and inversely correlates with the 
percentage of circulating TRegs – a key subset of lymphocytes involved in the suppression of 
immune and autoimmune responses that is reduced in patients with MS as compared with 
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healthy matched controls (114). Of note, the number of peripheral TRegs in patients with MS 
inversely correlates with the serum levels of leptin, suggesting a link between the number of 
TRegs and leptin secretion (114). Considering that TRegs are generated in the thymus, it is not 
known whether peripheral leptin or that produced in the perithymic adipose tissue could affect 
TRegs generation/function in autoimmunity-prone subjects. This aspect is not defined yet and 
is object of current extensive investigation. In any case, the fact that increased leptin secretion 
occurs in acute phases of MS and correlates with CSF production of IFN-γ is of possible 
interest for the pathogenesis and clinical follow-up of patients with MS. As mentioned before, 
increased leptin secretion is present both in the serum and in the CSF of patients with MS and 
does not correlate with body mass index (BMI) (114). The increase of leptin in the CSF is 
higher than in the serum, suggesting possible secondary in situ synthesis of leptin in the CNS 
and/or an increased transport across the blood–brain barrier following enhanced systemic 
production. A recent gene microarray analysis of Th1 lymphocytes from active MS lesions 
has shown elevated transcripts of many genes of the neuroimmunoendocrine axis, including 
leptin (115). Leptin transcripts were also abundant in gene expression profiles of human Th1 
clones, confirming that leptin gene transcription is induced concomitantly with the 
polarization toward Th1 responses – which are often involved in T-cell-mediated autoimmune 
diseases including MS. Moreover, in situ secretion of leptin near inflammatory T cells and 
macrophages was observed in active EAE lesions (113). A possible explanation for the in situ 
elevated levels of leptin in the CSF of patients with MS could be the inflammatory cell itself, 
as suggested by studies with autoreactive human myelin basic protein (hMBP)-specific T cells 
from patients with MS that produced leptin and upregulated the expression of leptin receptor 
after activation (114). Both anti-leptin and anti-leptin receptor-blocking antibodies reduced 
the proliferative responses of the hMBP-specific T cell lines to antigen stimulation, 
underlying a possibility of leptin-based intervention on this autocrine loop to block 
autoreactivity (114). Finally, recent reports (115) have shown increased secretion of serum 
leptin before relapses in patients with MS during treatment with IFN-β, and a capacity of 
leptin to enhance in vitro secretion of TNF-α, IL-6, and IL-10 from peripheral blood 
mononuclear cells of patients with MS in acute phase of the disease but not in patients with 
stable disease (116). In view of all these considerations, we suggest that leptin could be one of 
the many proinflammatory factors that act in concert to promote the pathogenic (autoreactive) 
Th1 responses targeting neuroantigens in MS. 
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Fig 5. Lymph node and CNS expression of leptin during acute/active EAE. A) Leptin expression in SJL/J 
female mouse adipose tissue used as positive control. (B and C) Expression of leptin in T cells and macrophages 
in a draining lymph node from SJL/J female mice after immunization with PLP139–151. D) Leptin was not 
expressed in the brain of C57BL/6J ob/ob mice after immunization with MOG35–55 peptide (n = 4). (E and F) 
Expression of leptin in inflammatory infiltrates (white square) and in choroid plexus (arrow) during the acute 
phase of EAE in C57BL/J6 WT mice (n = 4). (g) Leptin was not expressed in the brain of SJL/J male mice after 
immunization with PLP139–151 peptide (n = 6). (H and I). Leptin expression in inflammatory lesions in the 
acute phase of EAE in SJL/J female mice (n = 6). J) Cerebellum of SJL/J male mice did not express leptin after 
immunization with PLP139–151 peptide, whereas in k and l leptin was expressed in inflammatory infiltrates 
(white square) and choroid plexus (arrow) of SJL/J females. M) Spinal cord C57BL/J6 ob/ob mice immunized 
with MOG35–55 peptide did not express leptin. (N and O) Expression of leptin in neurons (white square in n) 
and two inflammatory infiltrates around blood vessels (arrows in n) detectable during the acute phase of EAE in 
C57BL/6J WT mice spinal cord. (P-R) Leptin expression was revealed in T cells present in inflammatory 
infiltrates of the brain, cerebellum, and spinal cord (arrows) of C57BL/J6 WT mice after adoptive transfer, but it 
was not detectable in the CNS of C57BL/6J ob/ob mice after adoptive transfer (not shown). The white squares in 
b, e, h, k, and n represent the zone of higher magnification shown in c, f, i, l, and o, respectively. 
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 AIM OF THE STUDY 
 As discussed before, leptin is a peptide hormone belonging to the helical cytokine family 
produced primarily from adipocytes, it has been shown to control food intake, basal 
metabolism and reproductive function (14). Experimental evidence supports a direct role for 
leptin in the regulation of immunity (117). Obese leptin-deficient (ob/ob) mice and leptin 
receptor (LepR)-deficient mice (db/db) mice, display numerous immune abnormalities (18, 
117), including mild-severe CD4+ T cell lymphopenia, increased absolute number of natural 
regulatory T (Treg) cells and resistance to a series of inducible or spontaneous autoimmune 
disorders such as experimental autoimmune encephalomyelitis (EAE) and type 1 diabetes in 
nonobese diabetic (NOD) mouse, respectively. Leptin enhances also T helper 1 (Th1) 
proinflammatory cytokine production in vivo and in vitro, conditional on the presence of a 
functional LepR (119).  
 Immune homeostasis, the maintenance of lymphocyte numbers, is critical factor for 
survival. In the thymus, developmental and maturation programs regulate thymocyte numbers 
and output. In the periphery, regulation of cell survival, proliferation and death ensure the 
maintenance of T cell numbers. Immune homeostasis is also critical to protect against self-
reactivity, which can arise as T cell receptors develop and diversify. Negative selection in the 
thymus, anergy and a variety of Treg cell populations manage these potentially autoreactive 
lymphocytes (120). 
 Loss of immune homeostasis, leading to abnormal lymphocyte numbers, can lead to various 
disease states.  In order to maintain peripheral T cell numbers, lymphocytes undergo 
homeostatic proliferation (121). Homeostatic proliferation occurs to maintain a full lymphoid 
compartment in numerous natural settings, such as in newborns, whose immune systems are 
still developing, and in the elderly, whose thymic output has decreased (122). The regulation 
of homeostatic proliferation is key for normal immune function. Cytokines, including IL-6, 
IL-7, IL-15 and IL-21, have all been implicated in homeostatic control (123, 124). Treg cells 
have also been implicated in the control of homeostatic proliferation, although their exact role 
remains controversial. Recent reports have shown that increased homeostatic proliferation 
associated with T cell lymphopenia can expand the pool of autoreactive T cells that promote 
autoimmunity (125, 128). In striking distinction, the observed CD4+ lymphopenia in ob/ob 
mice is not associated with an increased homeostatic proliferation of T cells leading to 
autoimmunity, rather to a resistance to break of self-tolerance leading to autoimmunity. 
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Our working hypothesis is that reduced susceptibility of ob/ob mice to autoimmunity and 
EAE could be ascribed to a reduced survival of autoreactive CD4+ T cells in an altered leptin-
deficient microenvironment.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 24 
Materials and Methods 
Mice and in vivo experiments 
 
 Female C57BL/6J wild-type (WT-B6) and C57/BL/6J-ob/ob (ob/ob) leptin deficient 
mice 8-10 week old were purchased from Charles River Italy (Calco, Italy) and from 
Harlan Italy (Correzana, Italy). The B10.Cg.Tg (TcrAND)53Hed/J (AND-TCR Tg) 
PCC-specific transgenic mice were purchased from The Jackson Laboratory (Barr 
Harbor, ME). WT-B6 and ob/ob mice were age matched for individual experiments 
and were group-housed two to six mice per standard cage according to different 
experimental condition, with a 12-h light-dark cycle. All experiments were performed 
under approved protocol in accordance with animal use guidelines of the Istituto 
Superiore di Sanità (Rome, Italy). 
 WT-B6 mice were injected intraperitoneally (i.p) with either leptin dissolved in 
(Sigma Aldrich) 200µL of PBS at a dose of 100µg/mouse and rapamacyn (Sigma 
Aldrich)  at a dose 100µg/mouse. 
 
Leptin administration 
 
 Mouse recombinant leptin (rleptin) was obtained from R&D Systems Europe (Oxon, 
U.K.); purity was >97%, assessed by SDS-PAGE and visualized by silver staining analysis. 
The endotoxin level was <0.1 ng/µg of leptin, as determined by the Limulus amebocyte lysate 
method. Mice comprised two groups (n = 6–11 per group) for ob/ob leptin-deficient obese 
mice (all housed in pairs) and one groups (n = 6–10 per group) for C57BL/6J normal age- and 
sex-matched control mice (housed two to six mice/cage). For adoptively induced disease, mice 
were treated starting 3 days before the transfer of MOG35-55 T cells and continuing over a 
period of 30 days. Of the groups of leptin-deficient mice, one was injected with 200 µl of PBS 
twice daily (at 10:00 a.m. and 6:00 p.m.); the second group was injected with murine rleptin 
(0.5 µg/g initial body weight twice daily in 200 µl volume i.p., for a total of 1 µg/g/day of 
rleptin); according to the same schedule (112, 129). For the group of WT-B6 mice, was 
injected with PBS twice daily according to the same schedule of obese mice. All mice were 
weighed and their food intake was recorded daily. 
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Antigens  
 
 The peptide used in this study were the immunodominant MOG35-55 peptide 
(MEVGWYRSPFSRVVHLYRNGK) and the PCC88-104 peptide 
(KAERADLIAYLKQATAK) (130). It was obtained from Inbios srl (Napoli, Italy) and purity 
was verified by HPLC (97% pure); the amino acid composition was assessed by mass 
spectrometry. In all experiment, we used MOG35-55 peptide and PCC88-104 peptide  from the 
same preparations, initially solubilized in LPS-free saline solution at 4 mg/ml concentration, 
and stored at -80°C. 
 
Induction of adoptive EAE  
 
 For induction of adoptive EAE (101), 10 female donor C57Bl/6J mice (6-8 week old) were 
primed s.c with 300 µg of MOG35-55 peptide in CFA distributed over four sites. After 9-10 
days, draining lymph nodes and spleen were harvested, homogenized into a single cell 
suspension, and cultured separately in vitro in 24-well plates (Falcon, Becton Dickinson, 
Franklin Lakes, NY) with RPMI 1640 medium (Life Technologies, Gaithersburg, MD) 
supplemented with 10% FBS (Life Technologies), 2 mM L-glutammine (Life Technologies),  
0.1 mM nonessential amino acids (Life Technologies), mM sodium pyruvate (Life 
Technologies), 50 µM 2-ME (Sigma), 100 U/ml penicillin, 100 µg/ml streptomycin (Life 
Technologies), and 25 µg/ml of MOG35–55 peptide. After 3 days in culture and addition to 
medium of 2 U/ml of rIL-2 (Roche Biochemicals, Monza, Italy), the cells were harvested and 
centrifuged over a Ficoll gradient (Pharmacia Biotech, Uppsala, Sweden) to remove debris 
Recipient syngeneic naive female leptin-deficient, PBS or rleptin treated, and WT-B6 control 
mice were i.v. injected with 2.5 x 106 T cells in a final volume of 500 µl of PBS. Mice also 
received 200 ng of pertussis toxin immediately after cell transfer and 1 day later.  
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Clinical assessment 
 
 Individual mice were observed daily for clinical signs of disease for up to 30 days after 
adoptive transfer. Mice were weighed and scored daily according to the clinical severity of 
symptoms. We used on a scale of 0 to 6 (112) by a "blinded" to mice identity experimenter, 
with 0.5 points for intermediate clinical findings: grade 0, no abnormality; grade 0.5, partial 
loss of tail tonicity, assessed by inability to curl the distal end of the tail; grade 1, reduced tail 
tone or slightly clumsy gait; grade 2, tail atony, moderately clumsy gait, impaired righting 
ability, or any combination of these signs; grade 3, hind limb weakness or partial paralysis; 
grade 4, complete hind limb paralysis or fore limb weakness; grade 5, tetraplegia or moribund 
state; grade 6, death. The data were plotted as daily mean clinical score for all animals in a 
particular treatment group. Scores of asymptomatic mice (score = 0) were included in the 
calculation of the daily mean clinical score for each group.  
 
 
Induction of delayed-type hypersensitivity (DTH) (footpad-swelling assay)  
 
 DTH responses to adoptively transferred MOG35–55 specific T cells were quantitated using 
a time-dependent footpad-swelling assay. Briefly, mice previously adoptively transferred with  
5x106 MOG35–55 specific CD4+ T cells were challenged by s.c. injection of into the right hind 
footpad 50µg MOG35-55 peptide . PBS alone was injected into the left footpad to serve as 
control for measurements. As negative control, we used immunized mice (sensitized with 
CFA alone). Footpad thickness was measured either after 7 days after transfer at 12, 24, 48, 
and 72 h after challenge, and for long-time DTH assessment footpad swelling was measured 
at respectively at 1, 7, 14 days by a "blinded" to sample identity experimenter using a caliper-
type engineer’s micrometer. The footpad-swelling response was calculated as the thickness of 
the right footpad (receiving Ag) minus the baseline thickness of the left footpad (receiving 
PBS).  
Cytokine measurement  
 Leptin, IL-7, IL-15 and IL-21 were measured using ELISA detection kits purchased from 
R&D Systems (Minneapolis, MN, USA), Bioo Scientific (Austin, TX USA) and Biolegend 
(San Diego CA USA), respectively. Measurements were performed according to the 
manufacturer's instructions. Soluble IL-1α, IL-2, IL-4, IL-5, IL-10, IL-17A, IFN-γ GM-CSF, 
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TNF-a, mouse cytokine were measured using beads based Analyte Detection Assay (Th1/Th2 
FlowCytomix Kit, Bender MedSystems, Vienna, Austria) according to the manufacturer's 
instructions.  
 
Proliferation assays 
 Spleen cells were obtained from mice at different time points after adoptive transfer, 
dissociated into single cell suspension, and cultured in flat-bottom 96-well microtiter plates 
(Falcon) at a density of 5x105 viable cells/well in a total volume of 200µl of RPMI 1640 
medium (Life Technologies), supplemented with 1% autologous mouse serum from each 
different groups of mice, 2 mM L-glutamine (Life Technologies), 0.1mM nonessential amino 
acids (Life Technologies), 1mM sodium pyruvate (Life Technologies), 50µM 2-ME (Sigma), 
100U/ml penicillin, and 100µg/ml streptomycin (Life Technologies). Cells were cultured at 
37°C in 100% humidity and 5% CO2 in the presence or absence of varying concentrations of 
MOG35–55 peptide (from 0 to 100µg/ml peptide). For experiments with AND-TCR-Tg mice 
DCEK transfectants (murine fibroblasts cells transfected with the Ek mouse class II molecule, 
(131) were used as antigen presenting cells to activate in vitro CD4+ AND-TCR-Tg mice T 
cells. T cells were incubated for 72h and an additional 16h, pulsed with 0.5µCi/well of 
[3H]thymidine (Amersham Pharmacia Biotech, Piscataway, NJ), harvested on glass-fiber 
filters using a Tomtec (Orange, CT) 96-well cell harvester, and counted in a 1205 Betaplate 
liquid scintillation counter (Wallac, Gaithersburg, MD). Results are expressed as mean cpm ± 
SD from triplicate cultures. 
Flow cytometry, cell sorting and biochemical analyses 
 CD4+ T cells from donor mice were stained with the fluorescent dye CFSE (5-, 6- 
carboxyfluorescein diacetate succinimidyl ester) from Molecular Probes (Eugene, OR) used at 
1µg/ml 5x106 CD4+ CFSE+-labelled T cells were injected in tail vein of WT-B6, ob/ob and 
leptin-treated ob/ob mice. For flow cytometric analyses of CFSE+ CD4+ T cells 7 and 14 days 
after transfer, spleen of three mice groups were harvested and 1x106 cells were analyzed to 
Facscalibur (Becton Dickinson, San Diego, USA) using CellQuest software (Becton 
Dickinson, San Diego, USA). For biochemical analyses (0.5-1x106) CD4+CFSE+ cells were 
obtained from the spleen of each group of WT, ob/ob and ob/ob-leptin-replaced mice, after 
High-Speed Cells Sorting (MoFlo, Dako, Denmark); cells were 99% pure. For western 
blotting, sorted cells were lysed in 50 mM HEPES (pH 7.5), 250 mM NaCl, 1 mM EDTA, 
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1.0% Triton X-100, 10 mM sodium fluoride, 1 mM sodium orthovanadate, and 2 µg/ml 
aprotinin, 2 µg/ml leupeptin, and 2 µg/ml pepstatin. 50 µg of total proteins were loaded on 
SDS-PAGE gel under reducing conditions. After electrophoresis, proteins were transferred 
onto a nitrocellulose filter membrane (Protan, Schleicher & Schuell) with a Trans-Blot Cell 
(Bio-Rad) and transfer buffer containing 25mM Tris, 192mM glycine, 20% methanol. 
Membranes were placed in 5% nonfat milk in PBS, 0.5% Tween 20 (PBST) at 4°C for 2 hr to 
block the nonspecific binding sites. Filters were incubated with specific antibodies before 
being washed three times in PBST and then incubated with a peroxidase-conjugated 
secondary antibody (Amersham Biosciences). After washing with PBST, peroxidase activity 
was detected with the ECL system (Amersham, Biosciences) or Femto (Pierce). The 
antibodies used were the following: anti-p27Kip-1, anti-pAKT, anti-AKT and anti-Bcl-2 and 
anti-PS6 (all from Cell Signaling Technology, Beverly, MA); all filters were quantified by 
densitometric analysis of the bands utilizing the program ScionImage 1.63 for Mac (Scion 
Corporation, Frederick, MD). Finally, FACS analyses for intracellular signalling were also 
performed by intracellular staining of P-S6, using Pe-conjugated P-S6 antibody (Cell 
Signaling Technology, Beverly, MA), was performed ex-vivo on CFSE+ cells after fixation 
and permeabilization procedures. 
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Results 
 
Chronic leptin deficiency associates with hypoplasia of lymphoid organs 
 
 We examined lymphoid organs in leptin-deficient (ob/ob), leptin-replaced ob/ob and 
wild-type (WT-B6) age-matched control mice. In ob/ob mice, thymus, spleen showed 
marked macroscopic hypoplasia as compared with normal WT counterparts and 
recombinant leptin-replaced ob/ob mice (Figure 6A). Microscopic analyses in ob/ob 
mice (hematoxylin&eosin) confirmed the atrophy of thymus in both cortical and 
medullar areas (Figure 6B). In addition, the spleen reduced in size and characterized by 
almost the absence of white pulp and primary follicles. These latter were confined only 
in the polar zones of the spleen (Figure 6B arrows). Finally, lymph nodes were very 
difficult to be found in ob/ob mice within the massive adipose tissue and the few that 
were isolated showed a marked “adipose-metaplasia”, in which the adipocytes 
represented the majority of cells (data not shown). In all the different lymphoid organs 
leptin-replacement restored both normal macroscopic and microscopic architecture 
(Figure 6A-B). 
 
 
Figure 6. Leptin deficiency is associates with hypoplasia of lymphoid organs.  
A) Macroscopic hypoplasia of spleen and thymun in ob/ob as compared with normal WT-B6 counterpats. B) 
Hemotoxylin&eosin staining of spleen, thymus and lymph node from WT-B6, ob/ob and ob/ob rleptin-treated 
mice.  
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Resistance to adoptively-transferred EAE in ob/ob mice associates with a progressive 
decline in the in vivo myelin-antigen-specific CD4+ T cell responses and reduced 
Th1/Th17 cytokine secretion 
 
 We have previously suggested that leptin is required for induction and progression of EAE 
(112). Our hypothesis is that leptin controls survival and proliferation of myelin-antigen-
specific CD4+ T cells. We adoptively transferred 5x106 encephalitogenic MOG35-55-specific 
CD4+ T lymphocytes into the tail veins of WT-B6, leptin-deficient ob/ob mice treated or not 
with mouse recombinant leptin (rleptin), respectively. As shown Figure 7A, MOG35-55-
specific CD4+ T cells were unable to transfer EAE when injected into ob/ob recipients. In 
contrast, these T cells induced EAE when transferred into WT-B6 and ob/ob treated with 
rLeptin, respectively, as suggested by a similar frequency of disease and clinical score in 
these groups of mice. We dissected in vivo and in vitro the magnitude, the efficiency and the 
progression overtime of the Th1-metiated immune response transferred by the MOG35-55-
specific T cells. More specifically, 7-days after adoptive transfer of MOG35-55-specific CD4+ 
T cells mice were challenged with 50µg of MOG35-55 peptide into the footpad to measure the 
delayed-type hypersensitivity (DTH) response. Ob/ob mice showed a reduced kinetics in the 
DTH reaction (12-72h) as compared with WT-B6 and rleptin treated ob/ob mice (Figure 7B). 
In addition, to evaluate whether leptin deficiency could influence DTH response over a long 
time frame, we analyzed at different days from the adoptive transfer (1, 7, and 14 days) the 
maintenance of footpad swelling in all the above mentioned groups.  MOG35-55-specific CD4+ 
T cells were unable to maintain DTH responses over time, when adoptively transferred into 
ob/ob mice (Figure 7C). Finally, to define whether leptin deficiency could affect ex-vivo 
proliferation of previously-transferred MOG35-55 specific T cells, we performed dose-
depended MOG35-55  specific in vitro stimulation of splenocytes pulsed with MOG35-55 from 
the three groups of mice. all in autologous mouse serum to preserve also in vitro the in vivo 
condition of leptin deficiency and/or treatment. Cell proliferation of WT-B6 cells obtained 
from ob/ob mice was strongly reduced at all the different concentrations of MOG35-55 peptide, 
whereas rleptin treatment restored the proliferative capacity (Figure 7D). Next, secretion of 
cytokines from WT-B6 MOG35-55-specific T cells obtained from ob/ob mice was reduced in 
terms of production of pro-inflammatory cytokines such as IL-1α, IL-2, IL-6, IFN-γ, TNF-α, 
GM-CSF, IL-17A , restored by rleptin administration (Figure 7E).  Leptin deficiency did not 
alter the production of IL-4 and IL-10 classical Th2/regulatory type cytokines by WT-B6 cells 
in response to MOG35-55 antigen, whereas IL-5 was reduced similarly to Th1 cytokines. 
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Finally, WT-B6 MOG35-55-specific CD4+ T cells from ob/ob mice showed impaired release of  
survival cytokines, IL-15 and IL-21, when stimulated in vitro with MOG35-55-specific peptide. 
The levels of IL-7 in vitro secretion were undetectable after MOG35-55-peptide stimulation. In 
addition, the level of surface expression of the IL-7 receptor  was not different in all three 
groups of mice (data not shown). 
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Fig. 7 Leptin deficiency associates with resistance to passively-induced EAE, reduced DTH responses and 
decreased proliferation of CD4+ MOG35-55 specific T cells. A) Mean clinical score of passively induced EAE 
disease in WT-B6, ob/ob-PBS treated and ob/ob-leptin treated mice. Only WT-B6 and ob/ob-leptin treated mice 
groups develop clinical signs of disease, and showed a similar disease score. ob/ob-PBS treated mice were 
resistant to EAE induction when adoptively transferred with 5x106 encephalitogenic MOG35-55-specific CD4+ T 
lymphocytes. ob/ob-leptin treated group were injected with rleptin starting 3 days before the transfer until day 
25. Data are representative of three independent experiments with similar results (n = 5 mice per group). B) DTH 
reaction in WT-B6, ob/ob-PBS treated and ob/ob-leptin treated mice. 7-days after adoptive transfer of MOG35-55-
specitif CD4+ T cells, mice were challenged 50mg of MOG35-55 peptide into the footpad to measure the delayed-
type hypersensitivity (DTH) response. C) DTH response over time, 7-14 days after adoptive transfer MOG35-55-
specitif CD4+ T. Data are representative of two independent experiments with similar results, showing the means 
± SD of footpad-swelling responses. *p < 0.001 compared with WT-B6. D) Dose-depended MOG35-55 specific in 
vitro stimulation of splenocytes pulsed with MOG35-55 from the three groups of mice previously adoptively 
transferred with pathogenic MOG35-55-specific CD4+. Data are representative of two independent experiments 
showing the means ± SD of footpad-swelling responses. *p < 0.05. E) In vitro cytokines release on cell culture 
supernatent upon MOG35-55 specific in vitro stimulation of splenocytes from the three groups of mice previously 
adoptively transferred with WT-B6 pathogenic MOG35-55-specific CD4+. 
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Leptin controls homeostasis and survival of autoreactive and antigen-specific CD4+ T 
cells 
 
To define whether leptin deficiency influences survival and proliferation in vivo  of MOG35-55-
specific CD4+ T cells, CD4+ T purified from immunized MOG35-55 peptide WT-B6 mice 7 
days after immunization were activated in vitro for three days with MOG35-55-specific peptide, 
CFSE-labeled and adoptively transferred into WT-B6, ob/ob and rleptin-treated ob/ob 
recipient mice, respectively (Figure 8). At different time points the cells were monitored 
longitudinally in the spleens; we analyzed the recovery of CFSE+ MOG35-55-specific CD4+ T 
cells in all groups of mice. Seven days post-transfer the percentage of CFSE+ CD4+ T cells in 
ob/ob mice was dramatically reduced when compared with the other groups (Figure. 8A-B). 
At later time points (day 14) post transfer CD4+ T cells further collapsed as suggested by a 
reduced percentage and number (Figure. 8B). As the in vivo expansion rate measured as 
CFSE dilution was similar among the groups we tested whether altered recovery of CFSE+ 
CD4+ T in ob/ob mice could be ascribed to their increased apoptotic rate, we evaluated the 
expression of Annexin-V apoptotic marker on surface of CFSE+ MOG35-55-specific CD4+ T 
cells recovered from the spleens of WT-B6, ob/ob treated or not with rleptin. We found that 
Annexin-V levels were significantly increased in WT-B6 CD4+ T cells derived from ob/ob 
mice (Figure 8C). 
 To expand and confirm our observations to an homogeneous and clonal T cell  population, 
we utilized also CD4+ cells from TCR transegnic mice (132) (AND-TCR-Tg) against pigeon 
cytochrome c peptide (PCC88-104) and analyzed their CFSE dilution and survival overtime. We 
adoptively transferred CFSE+ PCC88-104-specific CD4+ T cells after three days in vitro 
activation with the PCC88-104 peptide loaded on DCEK transfectants (104) into WT-B6, ob/ob 
treated or not with rleptin. Once again leptin deficiency was responsible of the reduced 
recovery of CFSE+ PCC88-104-specific CD4+ transgenic T cells from ob/ob mice (Figure 8D) 
at 7 and 14 days after transfer (Figure 8D-E). Levels of apoptosis measured as Annexin-V 
were increased in ob/ob mice similarly to autoantigen specifc MOG35-55 cells (data not 
shown).  
 35 
 
Figure 8.  Leptin affects homeostasis of antigen-specific CD4+ T cell 
Left Schematic model of the experimental procedure for MOG35-55 specific CD4+ T cells: WT-B6 mice were 
immunized with MOG35-55-petide. After 9-10 days, draining spleen CD4+ T cells were cultured in vitro, for 3 
days in presence of MOG35-55-petide. Next, 10 x 106 CD4+ T cells were stained with CFSE and injected i.v into 
WT-B6, ob/ob PBS-treated and ob/ob rLeptin-treated recipient mice. After 7 and 14 days mice were harvested 
and citofluorimetric analysis was performed. Right Schematic model of the experimental procedure for PCC88-
104 specific CD4+ T cells: WT-B6 mice were immunized with PCC88-104-petide. After 9-10 days, draining spleen 
CD4+ T cells were cultured in vitro, for 3 days in presence of PCC88-104-petide.. Next, 10 x 106 CD4+ T cells were 
stained with CFSE and injected i.v into WT-B6, ob/ob PBS-treated and ob/ob rLeptin-treated recipient mice. 
After 7 and 14 days mice were harvested and citofluorimetric analysis was performed. 
A) Representative flow cytometry plots of CFSE+ CD4+ T cells recovered in the spleen from WT-B6 (upper 
panel), ob/ob-PBS treated (middle panel) and ob/ob-leptin (lower panel) treated mice 7 days after adoptive 
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transfer of in vitro-activated MOG35-55-specific CFSE-labelled CD4+ T cells from WT-B6. B) Histograms 
represent the percentage (left) and absolute number (right) of CFSE+ T cells detected at 7 and 14 days post 
adoptive transfer in spleen and B6-WT (dark bars), ob/ob PBS-treated (blu bars) and ob/ob rleptin-treated mice 
(red bars). Data are representative of three independent experiments.  Data are shown as mean +/- SD. *p < 0.05. 
C) Representative flow cytometry plot of Annexin V staining CFSE+ CD4+ T cells recovered in the spleen from 
WT-B6 (upper panel), ob/ob-PBS treated (middle panel) and ob/ob-leptin (lower panel) treated mice 7 days after 
adoptive transfer of in vitro-activated MOG35-55-specific CFSE-labelled CD4+ T cells from WT-B6. Data are 
representative of three independent experiments and indicate the percentage of Annexin V+ cells. D) 
Representative flow cytometry plots of CFSE+ CD4+ T cells recovered in the spleen from WT-B6 (upper panel), 
ob/ob-PBS treated (middle panel) and ob/ob-leptin (lower panel) treated mice 7 days after adoptive transfer of in 
vitro-activated PCC88-104-specific CFSE-labelled CD4+ T cells from WT-B6. E) Histograms represent the 
percentage (left) and number (right) of CFSE+ T cells detected at 7 and 14 days  post adoptive transfer in spleen 
B6-WT (dark bars), ob/ob PBS-treated (blu bars) and ob/ob rLeptin-treated mice (red bars). Data are 
representative of three independent experiments. Data are shown as mean +/- SD. *p < 0.05. 
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Leptin deficiency associates with reduced expression of the survival gene Bcl-2, impaired 
activation of P-ERK1-2 pathway and increased expression of the cell cycle inhibitor 
p27kip1 
 
 To understand the intracellular molecules and biochemical pathway leading to impaired 
survival of MOG35-55-specific CD4+ T cells in leptin-deficient mice, we dissected the 
molecular pathways involved in cell survival and proliferation. Western blot analysis showed 
that FACS-sorted WT-B6 MOG35-55-specific CD4+ T cells, derived from ob/ob mice, 
displayed lower levels of the anti-apoptotic protein Bcl-2 and higher amount of cell cycle 
inhibitor p27Kip1 as compared to WT-B6 CD4+ T cells from WT-B6 and leptin-treated mice 
(Figure 9). Finally, leptin deficiency affected P-ERK1/2 pathway of WT-B6 MOG35-55-
specific CD4+ T cells transferred in ob/ob mice. These findings are in agreement with the 
increased apoptosis and cell cycle arrest observed in the condition of leptin deficiency.   
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Fig. 9 Leptin deficiency is associates with impaired ERK1/2 (P-ERK1/2) phosphorylation, reduced 
expression of survival gene Bcl-2 and increased expression of the cell cycle inhibitor p27kip1 in MOG35-55 
specific T cells 
Immunoblot for, phospho-ERK1/2 (P-ERK1/2), p27kip1, Bcl-2, on FACS-Sorted MOG35-55 CD4+ T cells from 
WT, ob/ob and ob/ob-treated mice 7 day post transfer, respectively. Graphs show quantitation of each specific 
protein. One representative out of three independent experiments is shown.  
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Leptin controls survival of antigen-specific autoreactive CD4+ T cells through the 
nutrient/energy-sensing AKT-mTOR pathway 
 
 Next, we tested whether leptin controls the expression of the protein kinase B (AKT) and 
its downstream enegy-sensing mTOR pathway (133, 135). We found that FACS-sorted 
MOG35-55-specific CD4+ T cells from ob/ob mice, displayed lower level of phosphorilation of 
both AKT and S6 ribosomal protein (S6) (Figure 10A), two important upstream and 
dowstream molecules involved in mTOR signalling cascade, respectively. These results on S6 
phosphorilation were also confirmed by flow cytometric detection of P-S6 on CFSE+ MOG35-
55-specific CD4+ T cells (Figure 10B ).  
 As the P-S6 appeared to be impaired by leptin deficiency we performed a series of 
experiments utilizing rapamycin, an mTOR specific inhibitor. Interestingly, acute/short term 
rapamycin (RAPA) treatment in vivo resembled the effects of leptin deficiency in terms of 
recovery of MOG35-55-specific CD4+ T in WT-B6 mice. Indeed, seven days after adoptive 
transfer of WT-B6 CFSE+ MOG35-55 pathogenic T cells into WT-B6 mice alternatively treated 
with PBS, RAPA, rleptin and rleptin+RAPA (Figure 11). RAPA treatment significantly 
reduced the number of WT-B6 CFSE+ MOG35-55 T cells and leptin treatment alone or with 
RAPA prevented reduction of these T cells. These effects were secondary to inhibition of the 
mTOR pathway and reversed by exogenous rleptin administration during RAPA treatment 
(Figure 11). 
 
 40 
 
Fig. 10 Leptin affects survival antigen-specific autoreactive CD4+ T cells through the nutrient/energy-
sensing AKT-mTOR pathway 
A) Immunoblot for pAKT, pS6 on FACS-Sorted MOG35-55 CD4+ T cells from WT, ob/ob and ob/ob-treated 
mice 7 day post transfer, respectively. Graphs show quantitation of each specific protein. One representative 
out of five independent experiments is shown.  
B)Flow cytometric analysis of S6 phosphorilation on FACS-Sorted CFSE+ MOG35-55 CD4+ T cells from WT-
B6 transferred into WT-B6 (left), ob/ob (middle)and ob/ob-treated (right) mice. MOG35-55 CD4+ T cells were 
sorted from the spleen of WT, ob/ob and ob/ob-treated mice respectively. CFSE+ MOG35-55 CD4+ T cells 
were than fixed and stained using P-S6-Phycoerytrine (PE) specific antibody. One representative out of three 
independent experiments is shown. (* p< 0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 41 
 
 
 
 
 
 
 
 
 
Figure 11. Rapamacyn treatment reduced the pool of MOG35-55-specific CD4+ T in WT-B6 mice upon 
adoptive transfer 
Number of  MOG35-55 CD4+ T  recovered in WT-B6 alternatively treated with PBS, RAPA, rleptin and 
rleptin+RAPA seven days post adoptive transfer (With Bars). Circulating Leptin levels in WT-B6 mice 
alternatively treated with PBS, RAPA, rleptin and rleptin+RAPA seven days post transfer (Black Bars). Bars 
represent mean + 3 SD of three replicates experiments. * p<0.05; **p<0.001 
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Discussion and Conclusion 
  In this study, we provide data suggesting that leptin is essential for survival of autoreactive, 
antigen-specific CD4+ T cells. Leptin deficient ob/ob mice were almost protected from 
adoptively-transferred EAE. Protection of ob/ob mice mirrored a progressive decline in 
survival of autoreactive myelin-peptide specific T cells and was associated with a reduced 
secretion of Th1/Th17 pro-inflammatory cytokines by CD4+ T cells from WT-B6 mice after 
they “experienced” an environment devoid of leptin in ob/ob mice. These effects were 
secondary to a significant downregulation of the survival protein Bcl-2, and associated with 
cell cycle arrest as testified by a reduction in the P-ERK1/2 and the upregulation of the cell 
cycle inhibitor p27kip1. In addition, as leptin activates the nutrient energy-sensing mTOR 
pathway (136), we investigated also the AKT-S6 levels in CD4+ T cells from WT-B6 
adoptively transferred into ob/ob mice. Interestingly, we observed a reduction in the P-AKT 
and P-S6 levels in these cells that was reversed by recombinant leptin treatment. As 
rapamycin-induced downregulation of the S6 levels and consequent reduction of circulating 
leptin in serum of normal WT-B6 mice, we enumerated the circulating CD4+ antigen-specific 
T cells following transfer before and after rapamycin treatment and observed a significant 
reduction of autoreactive myelin-specific T cells. These data suggest that either chronic leptin 
deficiency in ob/ob mice or induced leptin deficiency by rapamycin treatment are able to 
reduce survival of autoreactive T cells in mice through the impairment of the leptin-mTOR 
signalling. Our results indicate that nutritional status can affect and influence survival of 
potentially autoreactive T cells. This is in line with the epidemiological evidence that 
autoimmunity is more common in more effluent countries and that susceptibility to 
autoimmune diseases in some circumstances can correlate with body fat mass and body 
weight at birth (137). Moreover, other studies published by Fontana et al. (138) and our group 
have shown that nutritional deprivation or caloric restriction are able to profoundly modulate 
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and reduce magnitude and disease score during EAE (139, 140). The so called “frugal 
phenotype” in which survival of chronically food restricted mice is higher than freely feeding 
mice fits into this view, in which the environment can influence the break of immune 
tolerance through nutritional status and that interventions aimed at modulating cytokines and 
mediators of metabolism can have profound immunemodulating activities on autoimmune 
disease curse and progression. Similar results have also been obtained with chronic treatment 
with rapamycin of mice in which survival was increased significantly. The precise 
mechanisms for these results are still not fully clarified but it is clear that rapamycin treatment 
is able to induce pharmacologically a “frugal phenotype” similar to that observed in caloric 
restricted animals. Indeed, rapamycin, thorugh mTOR inhibition, is able to reduce the 
absorption of amino acids, glucose and also, to dampen the level of a series of adipocytokines 
produced by adipocytes including leptin (141). Also in our experimental settings we observed 
that rapamycin administration was able to reduce circulating leptin levels and survival of 
autoreactive T cells. Exogenous administration of leptin was able to partially revert the 
rapamycin-induced reduction of CD4+ T cells. 
 Leptin represents a nutritional signal in which the environment communicates to the center 
(the brain and hypothalamus) that sufficient amount of nutrients are present in the 
environment, and these are stored in form of fat depots. Factors involved in survival of 
autoreactive T cells are still not well characterized and specific microenvironmental 
requirements are not completely identified. In this context, one of the most recent advances 
are represented by the study of IL-21, a long helical cytokine, involved in survival and 
homeostatic proliferation of T cells and their possible conversion into autoreactive T cells 
(142). This view in ob/ob mice despite it is present a mild-to-severe lymphopenia homeostatic 
proliferation of autoreactive T cells is not present as IL-21. 
 In summary, our study demonstrates previously unrecognized role of leptin in survival of 
autoreactive antigen-specific T cells that mediate autoimmunity. Leptin regulates autoantigen-
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specific CD4+ T cell survival directly, through activation of the nutrient energy-sensing 
mTOR pathway and the survival gene Bcl-2, and indirectly, through a reduced secretion of 
cytokines important in T cell survival such as IL-6, IL-15, IL-21, GM-CSF. IL-7, another key 
cytokine in homeaostatic proliferation and survival, was not produced and detectable upon 
antigen stimulation by T cells that experienced a leptin-free environment, and also its receptor 
was not found different in terms of surface expression in all different group of mice treated or 
not with leptin (data not shown). Interestingly, IL-7 circulating serum levels were 
significantly higher in ob/ob mice (data not shown) suggesting that its secretion by other sites 
was increased to compensate the reduced number of CD4+ T cells observed in these mice. 
These data are in agreement with studies in which it has been suggested that in conditions of 
CD4+ T cell lymphopenia, IL-7 circulating concentration increase.  
 In conclusion, manipulation of the leptin axis can represent a novel tool for control of T 
cell tolerance and inflammation, and our study sets the molecular basis for a novel immune 
intervention in autoimmunity. 
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